Kane Biotech (CVE:KNE) Trading 14.3% Higher – Still a Buy?

Kane Biotech Inc. (CVE:KNEGet Free Report) shot up 14.3% on Thursday . The stock traded as high as C$0.04 and last traded at C$0.04. 180,000 shares were traded during trading, an increase of 97% from the average session volume of 91,506 shares. The stock had previously closed at C$0.04.

Kane Biotech Price Performance

The company has a market cap of C$6.65 million, a PE ratio of -0.44 and a beta of 0.23. The stock has a fifty day moving average price of C$0.04 and a 200-day moving average price of C$0.05. The company has a debt-to-equity ratio of -331.42, a current ratio of 0.80 and a quick ratio of 0.39.

About Kane Biotech

(Get Free Report)

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.

Featured Stories

Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.